Compare Sibanye Stillwater Ltd (SBSW) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs GeneDx Holdings Corp — how do they compare? Sibanye Stillwater Ltd trades at $10 (market cap $6.88B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Sibanye Stillwater Ltd is far larger — about 3.4× GeneDx Holdings Corp's market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sibanye Stillwater Ltd for 51 Days and GeneDx Holdings Corp for 19 Days on average.
| SBSW | WGS | |
|---|---|---|
Market Cap | $6.88B | $2.02B |
Volume | 4,474,536 | 734,640 |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $167.51 |
52-Week Low | $8.00 | $34.51 |
Typical Hold Time | 51 Days | 19 Days |
Enterprise Value | $7.78B | $2.05B |
Dividend Yield | 8.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sibanye Stillwater (SBSW) trades at $9.91, up 2.38% today, showing mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, the company reported strong revenue growth to $129.68 billion in 2025 with improving margins, though net income remains negative. Recent Q2 2026 earnings beat expectations with EPS of $1.34 versus $1.26 expected, indicating operational momentum. Analyst sentiment is cautiously optimistic with a Moderate Buy consensus and $14.25 price target representing 44% upside potential.
The stock presents a turnaround opportunity with attractive valuation metrics (P/E 8.12, P/S 0.7) and strong cash flow generation, but faces risks from volatile commodity prices and persistent negative earnings. Institutional ownership is growing with recent 81.4% position increase by MAC Alpha Capital. The key catalyst remains sustained profitability improvement and execution of the 2027-2028 growth roadmap.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
